This Article Full Text Full Text (PDF) Other Versions of this Article: JCM.00706-06v1 45/2/364    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carozzi, F. Articles by Confortini, M. Search for Related Content PubMed PubMed Citation Articles by Carozzi, F. Articles by Confortini, M.

Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay in Detection of High-Risk Human Papillomavirus and Diagnosis of Biopsy-Confirmed High-Grade Cervical Disease

Centro per lo Studio e la Prevenzione Oncologica, Analytical Cytology and BioMolecular Unit, Via Cosimo il Vecchio 2, 50127 Florence, Italy

Received 4 April 2006/ Returned for modification 12 June 2006/ Accepted 9 November 2006

The AMPLICOR HPV test (AMP) and the Hybrid Capture 2 assay (HC2) detect 13 high-risk human papillomavirus (HR-HPV) types. Evaluation of comparative performance with clinical samples is needed to allow informed implementation of AMP into clinical practice. AMP was used (i) to assess the prevalence of HR-HPV in 1,032 samples of known cytology, HC2 status, and/or confirmed histology; (ii) to determine agreement between AMP and HC2; (iii) to evaluate the clinical sensitivity and specificity for detecting HR-HPV; and (iv) to detect the presence of biopsy-confirmed high-grade cervical intraepithelial neoplasia. The prevalence of HR-HPV was 39.3% and 45.6% by AMP and HC2, respectively. Overall agreement was 89.2% (kappa value, 0.78). Of 509 HR-HPV-negative specimens by HC2, 488 (95.9%) were AMP negative. Of 427 HR-HPV-positive specimens by HC2, 347 (81.2%) were AMP positive. In comparing the ability to detect high-grade squamous intraepithelial lesions (HSIL), the two tests were positive for all HSIL samples. Both tests performed similarly on CIN2+ samples (clinical sensitivities were 96.7% and 97.8%, respectively, for AMP and HC2). The clinical specificities of AMP and HC2 were comparable (54.9% versus 51.6%; P = 0.18). Genotyping of 20 HC2-negative/AMP-positive cases using alternative technologies revealed target HR genotypes in 63.1% of cases and low-risk types in 15.7% of cases, while 21% of cases were negative. In conclusion, AMP provides a viable alternative to HC2, with good agreement for samples with high-grade cytology and similar sensitivity in detecting CIN2+ lesions.

Published ahead of print on 22 November 2006.

This article has been cited by other articles:

• Grisaru, D., Avidor, B., Niv, J., Marmor, S., Almog, B., Leibowitz, C., Graidy, M., Giladi, M. (2008). Pilot Study of Prevalence of High-Risk Human Papillomavirus Genotypes in Israeli Jewish Women Referred for Colposcopic Examination. J. Clin. Microbiol. 46: 1602-1605 [Abstract] [Full Text]  
• Castle, P. E., Sadorra, M., Garcia, F. A.R., Cullen, A. P., Lorincz, A. T., Mitchell, A. L., Whitby, D., Chuke, R., Kornegay, J. R. (2007). Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens. Cancer Epidemiol. Biomarkers Prev. 16: 840-843 [Abstract] [Full Text]